TRIM72 + human umbilical cord-derived mesenchymal stem cells
TRIM72 + human umbilical cord-derived mesenchymal stem cells has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Apr 30, 2022: “MG53 protein rejuvenates hUC-MSCs and facilitates their therapeutic effects in AD mice by activating Nrf2 signaling pathway”.
1 paper studies it2 findingsUpdated
- 1 lab in 1 country
- Funders: National Health Commission of the People's Republic of China and 1 more
- Animals1
What did studies of TRIM72 + human umbilical cord-derived mesenchymal stem cells find?
2Studies of TRIM72 + human umbilical cord-derived mesenchymal stem cells measured 2 outcomes; the most studied are amyloid-beta deposition (1 study) and cognitive function (1).
Amyloid-beta deposition
downin mice1
1 study
Amyloid-beta deposition
downin mice1
TRIM72 + human umbilical cord-derived mesenchymal stem cells decrease amyloid-beta deposition in mice.
“reduced Aβ deposition and Tau phosphorylation, promoted neurogenesis, and inhibited glia cells activation and oxidative stress”
Animalsin AD mice
Redox biology
Cognitive function
upin mice1
1 study
Cognitive function
upin mice1
TRIM72 + human umbilical cord-derived mesenchymal stem cells improve cognitive function in mice.
“MG53 combined with young hUC-MSCs transplantation alleviated cognitive deficit and depression-like behavior in AD mice”
Animalsin AD mice
Redox biology